Page last updated: 2024-11-12

thiopental sodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiopental sodium : An organic sodium salt having thiopental(1-) as the counter-ion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23665410
CHEBI ID9561
SCHEMBL ID34621
MeSH IDM0376292
PubMed CID12832575
CHEMBL ID738
MeSH IDM0376292
PubMed CID44607530
CHEMBL ID1229592
CHEBI ID61400
SCHEMBL ID93699
MeSH IDM0376292

Synonyms (160)

Synonym
sodium 5-ethyl-5-(1-methylbutyl)-4,6-dioxo-1,4,5,6-tetrahydropyrimidine-2-thiolate
thiopental, sodium salt
soluble thiopentone
trapanal sodium
5-ethyl-5-(1-methylbutyl)-2-thiobarbituric acid monosodium
intraval sodium
thiopentalum solubile
monosodium 5-ethyl-5-(1-methylbutyl) thiobarbiturate
sodium 5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate
thiomebumalnatrium
pentothal sodium
thiopental sodium salt
einecs 200-763-1
sodium (+-)-5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate
sodium pentothiobarbital
thiopentone sodium
thiopenton-natrium
4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt
tiopentale sodico [dcit]
sodium penthiobarbital
thiopentalum-natrium
sodium thiopental
nesdonal sodium
sodium thiopentobarbital
barbituric acid, 5-ethyl-5-(1-methylbutyl)-2-thio-, sodium salt
thiopentalum natricum [inn-latin]
thiothal sodium
tiopental sodium
sodium thiopentone
penthiobarbital sodium
4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt, (+-)-
thiopental sodique [inn-french]
tiopental sodico [inn-spanish]
NCGC00159524-01
pentothal (tn)
thiopental sodium (jp17/usp/inn)
D00714
NCGC00095773-01
SPECTRUM1900005
HMS2094G03
chebi:9561 ,
thiopentalum natricum
HMS503G07
sodium 5-ethyl-4,6-dioxo-5-(pentan-2-yl)-1,4,5,6-tetrahydropyrimidine-2-thiolate
thiopental sodique
tiopental sodico
thiopental sodium [usp:inn:jan]
nsc 759557
unii-49y44qzl70
tiopentale sodico
49y44qzl70 ,
dtxcid301744
cas-71-73-8
dtxsid1021744 ,
tox21_111741
CCG-39536
AWLILQARPMWUHA-UHFFFAOYSA-M
SCHEMBL34621
tox21_111741_1
NCGC00159524-02
pentothal sodium-potassium salt
KS-1432
AKOS025392174
Q410179
AKOS037653994
thiopental (acid)
monosodium 5-ethyl-5-((1rs)-1-methylbutyl)-4,6-dioxo-1,4,5,6-tetrahydropyrimidine-2-thiolate
thiopental sodique (inn-french)
thiopental sodium (usp monograph)
tiopental sodico (inn-spanish)
4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt, (+/-)
thiopental sodium (usp:inn:jan)
tiopental de sodio
n01af03
thiopental sodium (mart.)
thiopentalum natricum (inn-latin)
AC-787
thiopental sodium
71-73-8
farmotal
sodium pentothal
thiomebumal sodium
nesdonal
hypnostan
ravonal
trapanal
pentothal
leopental
nsc-759557
thiopentobarbitone sodium
CHEMBL738
thiopental sodium [vandf]
thiopental sodium [who-dd]
thiopentalum natricum [who-ip latin]
thiopental sodium [green book]
thiopental sodium [usp monograph]
sodium (+/-)-5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate
thiopental sodium [orange book]
thiopental sodium [inn]
thiopental sodium [mi]
thiopental sodium [who-ip]
thiopental sodium [mart.]
4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-, monosodium salt, (+/-)-
thiopental sodium [jan]
AKOS024386348
na-thiopental
sodium;5-ethyl-5-pentan-2-yl-2-sulfanylidenepyrimidin-3-ide-4,6-dione
HY-12026
chebi:61400 ,
CHEMBL1229592 ,
wz4002 ,
n-{3-[(5-chloro-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)oxy]phenyl}prop-2-enamide
n-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide
MLS003230945
smr001913510
bdbm50383274
wz-4002
wz 4002
HMS3265P16
HMS3265O16
HMS3265O15
HMS3265P15
NCGC00263144-02
NCGC00263144-01
6bq432z61m ,
unii-6bq432z61m
CS-0167
n-(3-((5-chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)acrylamide
S1173
1213269-23-8
n-[3-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide
SCHEMBL93699
MLS006011213
2-propenamide, n-(3-((5-chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)-
n-(3-((5-chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)-2-propenamide
n-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazine-1-yl)phenylamino)pyrimidin-4yloxy)phenyl)acrylam
n-(3-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide
AC-27472
DTXSID30153230
gtpl9176
n-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
AKOS025401946
J-523322
J-004480
EX-A416
HMS3654C16
wz4002, >=98% (hplc)
NCGC00263144-11
SW219315-1
FT-0730384
Q27089236
AS-19387
BCP02515
SB19360
n-[3-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide hbr
AMY370
CCG-264847
A25634
nsc-755927
nsc755927

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" However, these inhibitors have yet to prove clinically efficacious, and their toxicity in skin, reflecting activity against wild-type EGFR, may limit dosing required to effectively suppress EGFR T790M in vivo."( Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
intravenous anaestheticnull
intravenous anaestheticnull
tyrosine kinase inhibitorAny protein kinase inhibitor that interferes with the action of tyrosine kinase.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
organic sodium salt
organic sodium salt
pyrimidinesAny compound having a pyrimidine as part of its structure.
piperazines
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
RAR-related orphan receptor gammaMus musculus (house mouse)Potency5.95570.006038.004119,952.5996AID1159521
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency22.30800.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.10650.000214.376460.0339AID720691
pregnane X nuclear receptorHomo sapiens (human)Potency24.67020.005428.02631,258.9301AID1346982; AID1346985
GVesicular stomatitis virusPotency15.48710.01238.964839.8107AID1645842
67.9K proteinVaccinia virusPotency3.76190.00018.4406100.0000AID720579; AID720580
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.30960.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency15.48710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency15.48710.01238.964839.8107AID1645842
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency23.36170.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency16.93300.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency0.01540.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency13.45040.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency23.91850.00108.379861.1304AID1645840
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
tyrosine-protein kinase YesHomo sapiens (human)Potency4.87320.00005.018279.2586AID686947
Interferon betaHomo sapiens (human)Potency20.88390.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency13.45040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NUAK family SNF1-like kinase 1Homo sapiens (human)IC50 (µMol)0.02500.00130.29185.0900AID1845553
Tyrosine-protein kinase ABL1Mus musculus (house mouse)IC50 (µMol)12.98500.01082.80269.6900AID1365579; AID1365580
Epidermal growth factor receptorHomo sapiens (human)GI500.62760.00030.64943.5000AID1350814; AID1350815; AID1350816; AID1350817; AID1350820; AID1350821; AID1350822
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)0.55100.00000.536910.0000AID1129567; AID1129568; AID1129569; AID1204628; AID1204629; AID1204630; AID1241286; AID1241287; AID1241288; AID1264286; AID1264289; AID1298660; AID1298661; AID1365576; AID1365577; AID1365578; AID1390633; AID1390635; AID1390636; AID1390638; AID1445468; AID1445469; AID1445470; AID1458976; AID1458977; AID1458978; AID1483366; AID1483367; AID1483368; AID1483369; AID1583836; AID1583837; AID1583838; AID1599511; AID1715789; AID1715791; AID1760612; AID1760613; AID1760614; AID1760615; AID662478; AID662479; AID662480; AID662481; AID662482; AID748091; AID748093; AID748094; AID761601; AID761602; AID761603; AID770081; AID770082; AID770083; AID775622; AID775623; AID775624
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)0.04400.00010.545310.0000AID770082
Insulin receptorHomo sapiens (human)GI501.20000.19000.54501.2000AID1481348
Insulin-like growth factor 1 receptorHomo sapiens (human)GI501.30000.19000.60251.3000AID1481349
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)IC50 (µMol)0.04400.00010.07801.0240AID770082
Dipeptidyl peptidase 1Homo sapiens (human)IC50 (µMol)2.10000.03473.151510.0000AID1599510; AID1599557
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)IC50 (µMol)0.04400.00010.17362.5900AID770082
ALK tyrosine kinase receptorHomo sapiens (human)IC50 (µMol)0.99000.00010.310710.0000AID1583835
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epidermal growth factor receptorHomo sapiens (human)EC50 (µMol)0.22820.00200.99027.9300AID1583839; AID1583840; AID1583841; AID1583844; AID1583845
Epidermal growth factor receptorHomo sapiens (human)Kd0.04130.00011.351420.8270AID1625319; AID1625320; AID662483; AID662485; AID719892
Tyrosine-protein kinase JAK3Homo sapiens (human)Kd0.15000.00021.06888.7000AID1239472
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)EC50 (µMol)6.25800.02602.53246.2580AID1583842
ALK tyrosine kinase receptorHomo sapiens (human)EC50 (µMol)6.25800.00051.99846.2580AID1583842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (316)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 1Homo sapiens (human)
DNA damage responseNUAK family SNF1-like kinase 1Homo sapiens (human)
cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of myosin-light-chain-phosphatase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell population proliferationNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cellular senescenceNUAK family SNF1-like kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityInsulin receptorHomo sapiens (human)
positive regulation of protein phosphorylationInsulin receptorHomo sapiens (human)
positive regulation of receptor internalizationInsulin receptorHomo sapiens (human)
heart morphogenesisInsulin receptorHomo sapiens (human)
regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
protein phosphorylationInsulin receptorHomo sapiens (human)
receptor-mediated endocytosisInsulin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayInsulin receptorHomo sapiens (human)
learningInsulin receptorHomo sapiens (human)
memoryInsulin receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptorHomo sapiens (human)
epidermis developmentInsulin receptorHomo sapiens (human)
male gonad developmentInsulin receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationInsulin receptorHomo sapiens (human)
male sex determinationInsulin receptorHomo sapiens (human)
adrenal gland developmentInsulin receptorHomo sapiens (human)
positive regulation of cell migrationInsulin receptorHomo sapiens (human)
exocrine pancreas developmentInsulin receptorHomo sapiens (human)
receptor internalizationInsulin receptorHomo sapiens (human)
activation of protein kinase activityInsulin receptorHomo sapiens (human)
activation of protein kinase B activityInsulin receptorHomo sapiens (human)
cellular response to insulin stimulusInsulin receptorHomo sapiens (human)
glucose homeostasisInsulin receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin receptorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycogen biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycolytic processInsulin receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionInsulin receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
regulation of embryonic developmentInsulin receptorHomo sapiens (human)
positive regulation of glucose importInsulin receptorHomo sapiens (human)
symbiont entry into host cellInsulin receptorHomo sapiens (human)
protein autophosphorylationInsulin receptorHomo sapiens (human)
positive regulation of developmental growthInsulin receptorHomo sapiens (human)
positive regulation of meiotic cell cycleInsulin receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin receptorHomo sapiens (human)
positive regulation of respiratory burstInsulin receptorHomo sapiens (human)
cellular response to growth factor stimulusInsulin receptorHomo sapiens (human)
dendritic spine maintenanceInsulin receptorHomo sapiens (human)
amyloid-beta clearanceInsulin receptorHomo sapiens (human)
transport across blood-brain barrierInsulin receptorHomo sapiens (human)
neuron projection maintenanceInsulin receptorHomo sapiens (human)
regulation of female gonad developmentInsulin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptorHomo sapiens (human)
multicellular organism developmentInsulin receptorHomo sapiens (human)
positive regulation of kinase activityInsulin receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
cardiac atrium developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
immune responseInsulin-like growth factor 1 receptorHomo sapiens (human)
signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
axonogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of muscle cell apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cerebellum developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
hippocampus developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
establishment of cell polarityInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cytokinesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to vitamin EInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of osteoblast proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to zinc ion starvationInsulin-like growth factor 1 receptorHomo sapiens (human)
response to nicotineInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin-like growth factor 1 receptorHomo sapiens (human)
response to alkaloidInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
estrous cycleInsulin-like growth factor 1 receptorHomo sapiens (human)
transcytosisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to ethanolInsulin-like growth factor 1 receptorHomo sapiens (human)
regulation of JNK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
protein autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of axon regenerationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of DNA metabolic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to mechanical stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to estradiol stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to progesterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to testosterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to dexamethasone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of steroid hormone biosynthetic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular senescenceInsulin-like growth factor 1 receptorHomo sapiens (human)
dendritic spine maintenanceInsulin-like growth factor 1 receptorHomo sapiens (human)
amyloid-beta clearanceInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to L-glutamateInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of hepatocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to aldosteroneInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of cholangiocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to angiotensinInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to amyloid-betaInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to insulin-like growth factor stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
multicellular organism developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to glucose stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
endocardial cushion developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of cell adhesionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
peripheral nervous system developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of gene expressionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell differentiationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cranial nerve developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of secretionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cardiac muscle tissue developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell mediated cytotoxicityDipeptidyl peptidase 1Homo sapiens (human)
proteolysisDipeptidyl peptidase 1Homo sapiens (human)
apoptotic processDipeptidyl peptidase 1Homo sapiens (human)
immune responseDipeptidyl peptidase 1Homo sapiens (human)
response to organic substanceDipeptidyl peptidase 1Homo sapiens (human)
negative regulation of myelinationDipeptidyl peptidase 1Homo sapiens (human)
positive regulation of proteolysis involved in protein catabolic processDipeptidyl peptidase 1Homo sapiens (human)
positive regulation of microglial cell activationDipeptidyl peptidase 1Homo sapiens (human)
positive regulation of apoptotic signaling pathwayDipeptidyl peptidase 1Homo sapiens (human)
proteolysis involved in protein catabolic processDipeptidyl peptidase 1Homo sapiens (human)
neural crest cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nervous system developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
synapse assemblyReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lactationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
embryonic pattern specificationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
central nervous system morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
olfactory bulb interneuron differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
regulation of cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell fate commitmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein autophosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland epithelial cell differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland alveolus developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cardiac muscle tissue regenerationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein localization to cell surfaceReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
mitotic cell cycleEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
microtubule-based processEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
mitotic metaphase chromosome alignmentEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
attachment of spindle microtubules to kinetochoreEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
cell divisionEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
microtubule cytoskeleton organizationEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
signal transductionALK tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
phosphorylationALK tyrosine kinase receptorHomo sapiens (human)
hippocampus developmentALK tyrosine kinase receptorHomo sapiens (human)
adult behaviorALK tyrosine kinase receptorHomo sapiens (human)
swimming behaviorALK tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
regulation of apoptotic processALK tyrosine kinase receptorHomo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
neuron developmentALK tyrosine kinase receptorHomo sapiens (human)
negative regulation of lipid catabolic processALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityALK tyrosine kinase receptorHomo sapiens (human)
regulation of dopamine receptor signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
response to environmental enrichmentALK tyrosine kinase receptorHomo sapiens (human)
energy homeostasisALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of dendrite developmentALK tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationALK tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationALK tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityALK tyrosine kinase receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (89)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
p53 bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
metal ion bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
amyloid-beta bindingInsulin receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin receptorHomo sapiens (human)
insulin receptor activityInsulin receptorHomo sapiens (human)
insulin-like growth factor receptor bindingInsulin receptorHomo sapiens (human)
protein bindingInsulin receptorHomo sapiens (human)
ATP bindingInsulin receptorHomo sapiens (human)
GTP bindingInsulin receptorHomo sapiens (human)
protein domain specific bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor II bindingInsulin receptorHomo sapiens (human)
cargo receptor activityInsulin receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptorHomo sapiens (human)
insulin bindingInsulin receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin receptorHomo sapiens (human)
protein-containing complex bindingInsulin receptorHomo sapiens (human)
PTB domain bindingInsulin receptorHomo sapiens (human)
G-protein alpha-subunit bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
ATP bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
identical protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein-containing complex bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein transporter activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein tyrosine kinase activator activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ubiquitin protein ligase bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 1Homo sapiens (human)
protein bindingDipeptidyl peptidase 1Homo sapiens (human)
cysteine-type peptidase activityDipeptidyl peptidase 1Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 1Homo sapiens (human)
peptidase activator activity involved in apoptotic processDipeptidyl peptidase 1Homo sapiens (human)
phosphatase bindingDipeptidyl peptidase 1Homo sapiens (human)
chloride ion bindingDipeptidyl peptidase 1Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 1Homo sapiens (human)
protein-folding chaperone bindingDipeptidyl peptidase 1Homo sapiens (human)
cysteine-type endopeptidase activityDipeptidyl peptidase 1Homo sapiens (human)
transcription cis-regulatory region bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein homodimerization activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
molecular_functionEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
protein bindingEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
alpha-tubulin bindingEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
beta-tubulin bindingEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
microtubule bindingEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
protein bindingALK tyrosine kinase receptorHomo sapiens (human)
ATP bindingALK tyrosine kinase receptorHomo sapiens (human)
heparin bindingALK tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityALK tyrosine kinase receptorHomo sapiens (human)
identical protein bindingALK tyrosine kinase receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (81)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
fibrillar centerNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleusNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
cytoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
microtubule cytoskeletonNUAK family SNF1-like kinase 1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Mus musculus (house mouse)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nuclear envelopeInsulin receptorHomo sapiens (human)
nuclear lumenInsulin receptorHomo sapiens (human)
lysosomeInsulin receptorHomo sapiens (human)
late endosomeInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
caveolaInsulin receptorHomo sapiens (human)
external side of plasma membraneInsulin receptorHomo sapiens (human)
endosome membraneInsulin receptorHomo sapiens (human)
membraneInsulin receptorHomo sapiens (human)
dendrite membraneInsulin receptorHomo sapiens (human)
neuronal cell body membraneInsulin receptorHomo sapiens (human)
extracellular exosomeInsulin receptorHomo sapiens (human)
insulin receptor complexInsulin receptorHomo sapiens (human)
receptor complexInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
axonInsulin receptorHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
caveolaInsulin-like growth factor 1 receptorHomo sapiens (human)
membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
T-tubuleInsulin-like growth factor 1 receptorHomo sapiens (human)
neuronal cell bodyInsulin-like growth factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleInsulin-like growth factor 1 receptorHomo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexInsulin-like growth factor 1 receptorHomo sapiens (human)
receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
protein kinase complexInsulin-like growth factor 1 receptorHomo sapiens (human)
axonInsulin-like growth factor 1 receptorHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
extracellular spaceReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
lateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
extracellular regionDipeptidyl peptidase 1Homo sapiens (human)
extracellular spaceDipeptidyl peptidase 1Homo sapiens (human)
nucleoplasmDipeptidyl peptidase 1Homo sapiens (human)
lysosomeDipeptidyl peptidase 1Homo sapiens (human)
endoplasmic reticulum lumenDipeptidyl peptidase 1Homo sapiens (human)
centrosomeDipeptidyl peptidase 1Homo sapiens (human)
membraneDipeptidyl peptidase 1Homo sapiens (human)
COPII-coated ER to Golgi transport vesicleDipeptidyl peptidase 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneDipeptidyl peptidase 1Homo sapiens (human)
azurophil granule lumenDipeptidyl peptidase 1Homo sapiens (human)
intracellular membrane-bounded organelleDipeptidyl peptidase 1Homo sapiens (human)
collagen-containing extracellular matrixDipeptidyl peptidase 1Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 1Homo sapiens (human)
lysosomeDipeptidyl peptidase 1Homo sapiens (human)
extracellular spaceDipeptidyl peptidase 1Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
extracellular regionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial matrixReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic density membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
glutamatergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA-ergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
microtubule organizing centerEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
cytosolEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
microtubuleEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
microtubule cytoskeletonEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
membraneEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
midbodyEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
mitotic spindleEchinoderm microtubule-associated protein-like 4Homo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
extracellular exosomeALK tyrosine kinase receptorHomo sapiens (human)
protein-containing complexALK tyrosine kinase receptorHomo sapiens (human)
receptor complexALK tyrosine kinase receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (329)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1713428Hypnotic activity in mouse assessed as onset of sleep time at 0.2 mmol/Kg, ip by righting reflex2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis, biological evaluation and molecular modeling study of thiadiazolo[3,2-a][1,3]diazepine analogues of HIE-124 as a new class of short acting hypnotics.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1713422Hypnotic activity in mouse assessed as duration of sleep time at 0.2 mmol/Kg, ip by righting reflex2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis, biological evaluation and molecular modeling study of thiadiazolo[3,2-a][1,3]diazepine analogues of HIE-124 as a new class of short acting hypnotics.
AID1713435Therapeutic Index, ratio of LD50 of Toxicity in iv dosed mouse to minimum effective hypnotic dose in mouse2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis, biological evaluation and molecular modeling study of thiadiazolo[3,2-a][1,3]diazepine analogues of HIE-124 as a new class of short acting hypnotics.
AID316350Hypnotic effect in mouse assessed as sleeping time at 65 mg/kg, ip2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
New ultra-short acting hypnotic: synthesis, biological evaluation, and metabolic profile of ethyl 8-oxo-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-carboxylate (HIE-124).
AID109886Duration of analgesic action in mice was determined; B = brief, < 5 min1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID316340Hypnotic effect in mouse assessed as sleeping time at 50 mg/kg, iv by loss of righting reflex method2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
New ultra-short acting hypnotic: synthesis, biological evaluation, and metabolic profile of ethyl 8-oxo-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-carboxylate (HIE-124).
AID114273Hypnotic activity was measured as dose which causes loss of righting reflex for a minimum period of 30s in 50% of mice; Range is 20-251980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID119873Speed of induction of analgesia in mice was determined; I = immediate, <10 s1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID1713434Toxicity in iv dosed mouse measured upto 6 hrs2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis, biological evaluation and molecular modeling study of thiadiazolo[3,2-a][1,3]diazepine analogues of HIE-124 as a new class of short acting hypnotics.
AID116737Acute toxicity measured as median lethal dose in mice; Range is 80-901980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1129570Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1239424Antiproliferative activity against mouse BA/F3 cells expressing TEL-JAK3 after 72 hrs by cell titer glo assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Development of Selective Covalent Janus Kinase 3 Inhibitors.
AID1445475Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1129579Stability of the compound in rat plasma assessed as compound remaining at 50 uM at pH 7.4 after 24 hrs by LC-UV analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1365571Inhibition of recombinant human GSt-tagged EGFR T790M/L858R mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system at 10 uM using tyr 04 as substrate after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID748063Inhibition of NFkappaB phosphorylation in gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant at 0.01 to 1 uM after 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1129581GSH reactivity assessed as compound remaining at 50 uM after 1 hr at pH 7.4 by LC-UV analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID662584Inhibition of EGFR del E746-A750 mutant in human HCC827 cells assessed as change in EGFR level up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID775622Inhibition of EGFR T790M/L858R double mutant (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID1350816Inhibition of TEL-fused EGFR T790M mutant (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1583837Inhibition of GST-tagged human EGFR T790M mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID1350815Inhibition of TEL-fused EGFR C797S mutant (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1350820Inhibition of full length EGFR L858R mutant (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1350830Antiproliferative activity against human PC9 cells harboring EGFR del19 mutant after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1241288Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
AID552138Antiproliferative activity against mouse BA/F3 cells transfected with EGFR L858R/T790M mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID761588Inhibition of EGFR phosphorylation in human NCI-H1975 cells assessed as reduction of phosphorylated Akt level at 1 uM after 6 hrs by Western blotting analysis2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1298672Selectivity ratio, ratio IC50 for human A431 cells overexpressing wild-type EGFR to IC50 for human NCI-H1975 cells expressing EGFR T790M/L858R mutant2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
AID1445469Inhibition of human N-terminal GST-fused EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 25 mins by HTFR assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID552139Antiproliferative activity against mouse BA/F3 cells transfected with EGFR L858R/T790M/C797S mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1625321Selectivity ratio of Kd for wild type partial length human EGFR to Kd for partial length human EGFR L858R/T790M double mutant2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1760611Inhibition of recombinant NAMPT (unknown origin) using nicotinamide and pyrophosphate as substrate incubated for 60 mins and measured for 30 mins at 5 mins interval by colorimetric assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1599511Inhibition of EGFR (unknown origin) using biotin-labelled peptide as substrate preincubated for 2 hrs followed by substrate addition and measured after 30 mins by HTRF FRET assay2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
AID1129569Inhibition of EGFR L858R/T790M mutant (unknown origin) after 1.5 hr by FRET-based Z-lyte assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1264283Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1350835Antiproliferative activity against human NCI-H1355 cells harboring wild-type EGFR after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1458982Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID662508Inhibition of EGFR L858R/T790M mutant Y1068 autophosphorylation in human NCI-H1975 cells after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1481348Inhibition of Tel-fused INSR (unknown origin) expressed in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1241286Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
AID662510Inhibition of EGFR L858R/T790M mutant-mediated Akt phosphorylation in human NCI-H1975 cells up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1365579Inhibition of ABL in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1625334Potency index, ratio of gefitinib IC50 to compound IC50 for gefitinib resistant mouse BA/F3 cells expressing EGFR L858R/T790M double mutant2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1760612Inhibition of N-terminal GST-tagged human recombinant EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID770080Selectivity ratio of IC50 for wild type EGFR phosphorylation in human LoVo cells over IC50 for EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID662512Inhibition of EGFR L858R/T790M mutant-mediated Erk phosphorylation in human NCI-H1975 cells up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1625330Antiproliferative activity against gefitinib sensitive mouse BA/F3 cells expressing EGFR exon 19 del E746_A750 activating mutant after 72 hrs by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID748065Inhibition of EGFR L858R/T90M double mutant phosphorylation in gefitinib-resistant human NCI-H1975 cells assessed as inhibition of AKT phosphorylation at 0.01 to 1 uM after 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1365567Inhibition of recombinant human N-terminal GST/HIS6-tagged EGFR 746 to 750 deletion mutant (672 to 1210 residues) expressed in Sf9 insect cells at 10 uM using tyr 04 as substrate measured after 1 hr by LanthaScreen assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID662596Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID775613Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID1760614Inhibition of N-terminal GST-tagged human recombinant EGFR L861Q mutant (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1390633Inhibition of EGFR L858R/T790M mutant phosphorylation in human NCI-H1975 cells after 1 hr by ELISA
AID1365564Inhibition of wild-type recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system at 1 uM using tyr 04 as substrate measured after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1129567Inhibition of EGFR (unknown origin) after 1.5 hr by FRET-based Z-lyte assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1350829Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID748092Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1625333Selectivity ratio of IC50 for gefitinib sensitive mouse BA/F3 cells expressing wild type EGFR to IC50 for gefitinib resistant mouse BA/F3 cells expressing EGFR L858R/T790M double mutant2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID748094Inhibition of EGFR L858R mutant (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID761598Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1350831Antiproliferative activity against human HCC827 cells harboring EGFR del19 mutant after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1129577Chemical stability of the compound in buffer solution assessed as compound remaining at 50 uM at pH 7.4 after 24 hrs by LC-UV analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1204630Inhibition of GST-tagged human recombinant EGFR catalytic domain (668 to 1210 amino acids) T790M/L858R mutant expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay2015Bioorganic & medicinal chemistry, Jun-15, Volume: 23, Issue:12
Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
AID748093Inhibition of EGFR L858R/T90M double mutant (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID748088Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1298660Inhibition of wild-type EGFR (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
AID1372109Selectivity ratio of IC50 for human EGFR T790M mutant to IC50 for human wild type EGFR2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.
AID1583838Inhibition of GST-tagged human EGFR T790M/L858R double mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID662580Inhibition of EGFR del E746-A750 mutant-mediated Erk phosphorylation in human HCC827 cells up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID748075Induction of NO production in human 16HBE14o- cells harboring wild type EGFR assessed as increase in nitrite level at 100 uM after 150 mins by Griess assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID748087Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1365573Inhibition of recombinant human GST-tagged EGFR C797S mutant cytoplasmic domain (695 to end residues) expressed in insect cells at 10 uM using tyr 04 measured after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID552134Inhibition of Jak2 transfected with TEL fusion in mouse BA/F3 cells2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1365580Inhibition of ABL T315I mutant in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID662588Inhibition of EGFR del E746-A750 mutant in human HCC827 cells assessed as change in Akt level up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1470861Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1458979Selectivity ratio of IC50 for wild type N-terminal GST-fused human EGFR cytoplasmic domain to IC50 for human recombinant GST-tagged EGFR L858R/T790M double mutant2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1760613Inhibition of N-terminal GST-tagged human recombinant EGFR T790M mutant (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1715791Inhibition of recombinant human N-terminal GST tagged EGFR L858R mutant (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID662582Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as change in EGFR level up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID761600Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID662590Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as change in Erk level up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1298661Inhibition of EGFR T790M/L858R mutant (unknown origin) expressed in baculovirus expression system after 1 hr by ELISA2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
AID748064Inhibition of EGFR L858R/T90M double mutant phosphorylation in gefitinib-resistant human NCI-H1975 cells assessed as inhibition of ERK phosphorylation at 0.01 to 1 uM after 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1129568Inhibition of EGFR L858R mutant (unknown origin) after 1.5 hr by FRET-based Z-lyte assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1458984Selectivity ratio of EC50 for human A431 cells expressing wild type EGFR to EC50 for human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1129583L-cysteine reactivity assessed as compound remaining at 50 uM after 1 hr at pH 7.4 by LC-UV analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID662592Inhibition of EGFR del E746-A750 mutant in human HCC827 cells assessed as change in Erk level up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1445470Inhibition of human N-terminal GST-fused EGFR T790M/L858R double mutant (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 20 mins by HTFR assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1350838Antiproliferative activity against CHO cells after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID662483Binding affinity to EGFR2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1264284Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID748072Induction of apoptosis in gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant after 24 hrs by annexin-V/7-AAD staining-based FACS flow cytometric analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1583841Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID748070Induction of apoptosis in EGFR-independent human H460 cells at 1 to 5 uM after 24 hrs by annexin-V/7-AAD staining-based FACS flow cytometric analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1481311Growth inhibition of mouse BAF3 cells after 72 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1583842Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID1239473Antiproliferative activity against mouse BA/F3 cells expressing TEL-JAK3 after 72 hrs by MTS assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Development of Selective Covalent Janus Kinase 3 Inhibitors.
AID1483368Inhibition of EGFR L858R mutant (unknown origin)2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID1129572Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID770083Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID662598Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1458977Inhibition of human recombinant GST-tagged EGFR L858R mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 15 mins by HTRF assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1760615Inhibition of N-terminal GST-tagged human recombinant EGFR L858R mutant (668 to 1210 residues) expressed in baculovirus expression system by Z'-LYTE kinase assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
AID1350813Antiproliferative activity against mouse BAF3 cells after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1483369Inhibition of EGFR L858R/T790M double mutant (unknown origin)2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID1264286Inhibition of human recombinant EGFR T790M/L858R double mutant preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1845553Inhibition of N-terminal GST-tagged wild type human NUAK1 expressed in Escherichia coli DH5alpha incubated for 30 mins in presence of gamma-[32P]ATP by cerenkov counting analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Development and Therapeutic Potential of NUAKs Inhibitors.
AID1350821Inhibition of full length EGFR L858R/T790M mutant (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID748086Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1583845Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID1625320Binding affinity to partial length human EGFR L858R/T790M double mutant expressed in mammalian system by KINOMEscan assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID552132Antiproliferative activity against EGFR-deficient human PC9 cells2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID748089Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID748071Induction of apoptosis in gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant after 24 hrs by annexin-V/7-AAD staining-based FACS flow cytometric analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID552135Inhibition of Jak3 transfected with TEL fusion in mouse BA/F3 cells2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1129578Chemical stability of the compound in buffer solution assessed as compound remaining at 50 uM at pH 9 after 24 hrs by LC-UV analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1708306Antiproliferative activity against human NCI-H1975 cells2021European journal of medicinal chemistry, Feb-15, Volume: 212Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
AID1625319Binding affinity to wild type partial length human EGFR expressed in bacterial system by KINOMEscan assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1470862Selectivity index, ratio of IC50 for human A549 cells harboring wild type EGFR to IC50 for human NCI-H1975 cells harboring EGFR L858R/T790M double mutant2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID1365577Inhibition of EGFR E746_A750 deletion/T790M mutant in human growth-resistant PC9 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID552141Antiproliferative activity against mouse BA/F3 cells transfected with EGFR E746_A750_del/T790M/C797S mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1298671Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
AID1715789Inhibition of recombinant human N-terminal GST tagged EGFR L858R/T790M double mutant (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by T2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1239474Antiproliferative activity against mouse BA/F3 cells expressing EGFR L858R/T790M double mutant after 72 hrs by MTS assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Development of Selective Covalent Janus Kinase 3 Inhibitors.
AID775624Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID1583844Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID1458981Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID662600Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID662480Inhibition of EGFR L858R mutant after 1.5 hr by FRET assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1390636Inhibition of recombinant human GST-tagged EGFR L858R/T790M mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay
AID1390635Inhibition of recombinant human GST-tagged wild-type EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using tyrosine04 peptide as substrate after 60 mins in presence of ATP by Z-LYTE assay
AID662481Inhibition of EGFR L861Q mutant after 1.5 hr by FRET assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1239472Binding affinity to JAK3 (unknown origin)2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Development of Selective Covalent Janus Kinase 3 Inhibitors.
AID1625328Antiproliferative activity against gefitinib resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant after 72 hrs by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1129574Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1390641Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay
AID1365566Inhibition of recombinant human N-terminal GST/HIS6-tagged EGFR 746 to 750 deletion mutant (672 to 1210 residues) expressed in Sf9 insect cells at 1 uM using tyr 04 as substrate measured after 1 hr by LanthaScreen assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID770081Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID1583843Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID748090Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID662478Inhibition of EGFR after 1.5 hr by FRET assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1129582DTT reactivity assessed as compound remaining at 50 uM after 1 hr at pH 7.4 by LC-UV analysis2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1350834Antiproliferative activity against human NCI-H2122 cells harboring wild-type EGFR after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1365568Inhibition of recombinant human GST-tagged EGFR T790M mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system at 1 uM using tyr 04 as substrate after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID552140Antiproliferative activity against mouse BA/F3 cells transfected with EGFR E746_A750_del/T790M mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1129575Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1483367Inhibition of wild-type EGFR (unknown origin)2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID1350832Antiproliferative activity against human H3255 cells harboring EGFR L858R mutant after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1129573Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID1365578Inhibition of EGFR in human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID662599Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID552136Inhibition of Blk transfected with TEL fusion in mouse BA/F3 cells2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1625324Selectivity ratio of IC50 for human A431 cells expressing wild type EGFR to IC50 for human NCI-H1975 cells expressing EGFR L858R/T790M double mutant2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1470859Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID770082Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
AID748091Inhibition of wild type EGFR (unknown origin) after 1.5 hrs by FRET-based Z'Lyte assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID761596Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID748060Antitumor activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant xenografted in athymic BALB/c nude mouse assessed as tumor growth inhibition at 8 mg/kg, ip qd administered for 14 days measured every other day d2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1204628Inhibition of wild type N-terminal His6-tagged human EGFR kinase domain (702 to 1016 residues) expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay2015Bioorganic & medicinal chemistry, Jun-15, Volume: 23, Issue:12
Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
AID1673938Growth inhibition of human HN11 cells harboring wild type EGFR after 72 hrs by MTS assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
AID1483366Inhibition of recombinant human N-terminally GST-tagged EGFR L858R/T790M/C797S triple mutant expressed in baculovirus in Sf9 insect cells preincubated for 20 mins followed by addition of [33P]-ATP measured after 2 hrs by filter-binding method2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
AID1715790Inhibition of recombinant human N-terminal GST tagged EGFR d746-750 mutant (669 to 1210 residues) expressed in insect expression system using peptide as substrate incubated for 2 hrs followed by substrate addition and measured after 30 mins by TR-FRET ass2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
AID1625331Antiproliferative activity against mouse BA/F3 cells expressing wild type EGFR after 72 hrs by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID748066Inhibition of EGFR L858R/T90M double mutant phosphorylation in gefitinib-resistant human NCI-H1975 cells at 0.01 to 1 uM after 24 hrs by Western blot analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1365569Inhibition of recombinant human GST-tagged EGFR T790M mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system at 10 uM using tyr 04 as substrate after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID552133Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1350817Inhibition of full length EGFR del19 mutant (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID719892Binding affinity to recombinant EGFR L858R/T90M mutant2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Irreversible protein kinase inhibitors: balancing the benefits and risks.
AID1583836Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID1445476Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1365575Inhibition of recombinant human GST-tagged EGFR C797S L858R mutant cytoplasmic domain (695 to end residues) expressed in insect cells at 10 uM using tyr 04 measured after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID662509Inhibition of EGFR del E746-A750 mutant Y1068 autophosphorylation in human HCC827 cells after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1264285Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID761602Inhibition of EGFR L858R mutant (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1458983Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1390638Inhibition of wild-type EGFR phosphorylation in human A431 cells preincubated for 1 hr followed by EGF stimulation measured after 45 mins by ELISA
AID1458980Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1298670Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by SRB assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
AID1365576Inhibition of EGFR E746_A750 deletion mutant in human PC9 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1599557Inhibition of cathepsin C (unknown origin)2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
AID1264289Inhibition of wild type recombinant human EGFR preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID775623Inhibition of EGFR L858R mutant (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET-based Z'-LYTE assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID1264287Inhibition of human recombinant EGFR T790M/delE746_A750 double mutant preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID662578Inhibition of EGFR del E746-A750 mutant-mediated Akt phosphorylation in human HCC827 cells up to 125 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID761587Inhibition of EGFR phosphorylation in human NCI-H1975 cells assessed as reduction of phosphorylated Erk level at 1 uM after 6 hrs by Western blotting analysis2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID748076Induction of NO production in human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as increase in nitrite level at 100 uM after 150 mins by Griess assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
AID1481349Inhibition of Tel-fused IGF1R (unknown origin) expressed in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
AID1625332Antiproliferative activity against gefitinib resistant human PC9 cells expressing EGFR del E746_A750/T790M mutant after 72 hrs by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1599510Inhibition of CatL-activated recombinant human C-terminal His10-tagged cathepsin C (25 to 463 residues) expressed in mouse myeloma cells using Gly-Phe-AFC as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
AID1241287Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
AID552137Inhibition of Bmx transfected with TEL fusion in mouse BA/F3 cells2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1458976Inhibition of wild type N-terminal GST-fused human EGFR cytoplasmic domain expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 25 mins by HTRF assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1390640Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay
AID1129571Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
AID761603Inhibition of wild type EGFR (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1625329Antiproliferative activity against gefitinib resistant mouse BA/F3 cells expressing EGFR L858R/T790M double mutant after 72 hrs by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1625323Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M double mutant by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID761601Inhibition of EGFR L858R/T790M mutant (unknown origin) using Tyr 4 peptide as substrate after 1.5 hrs by FRET based Z'-lyte assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1204629Inhibition of GST-tagged human recombinant EGFR catalytic domain (668 to 1210 amino acids) L858R mutant expressed in Sf9 cells pre-incubated for 30 mins before ATP and substrate addition by homogeneous time-resolved FRET assay2015Bioorganic & medicinal chemistry, Jun-15, Volume: 23, Issue:12
Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
AID1708231Antiproliferative activity against human PC-9 cells2021European journal of medicinal chemistry, Feb-15, Volume: 212Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
AID1264290Selectivity ratio of IC50 for human recombinant EGFR T790M/L858R double mutant to IC50 for wild type recombinant human EGFR2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID775614Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
AID662586Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as change in Akt level up to 500 nM after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID662597Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1470860Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
AID761597Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID662482Inhibition of EGFR L858R/T790M mutant after 1.5 hr by FRET assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1350839Antiproliferative activity against CHL cells after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1583835Inhibition of GST-tagged human ALK cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID662485Binding affinity to EGFR L858R mutant2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1365574Inhibition of recombinant human GST-tagged EGFR C797S L858R mutant cytoplasmic domain (695 to end residues) expressed in insect cells at 1 uM using tyr 04 measured after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1350822Inhibition of full length EGFR L858R/T790M/C797S mutant (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1264288Inhibition of human recombinant EGFR T790M mutant preincubated for 10 mins followed by FAM-labeled peptide/ATP addition measured after 1 hr by mobility shift assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
AID1365565Inhibition of wild-type recombinant human GST-tagged EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system at 10 uM using tyr 04 as substrate measured after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID552142Antiproliferative activity against mouse BA/F3 cells transfected with EGFR E746_A750/T790M mutant2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Discovery of selective irreversible inhibitors for EGFR-T790M.
AID1445477Inhibition of human EGFR T790M/C797S/L858R triple mutant preincubated for 20 mins followed by [33P]ATP addition measured after 2 hrs2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID1350814Inhibition of TEL-fused EGFR (unknown origin) expressed in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1673937Growth inhibition of human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTS assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
AID1583840Inhibition of EGFR exon19 deletion mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID662479Inhibition of EGFR T790M mutant after 1.5 hr by FRET assay2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1365572Inhibition of recombinant human GST-tagged EGFR C797S mutant cytoplasmic domain (695 to end residues) expressed in insect cells at 1 uM using tyr 04 measured after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID761589Inhibition of EGFR phosphorylation in human NCI-H1975 cells at 0.01 to 1 uM after 6 hrs by Western blotting analysis2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1625335Potency index, ratio of gefitinib IC50 to compound IC50 for gefitinib resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID1583839Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Discovery of a potent dual ALK and EGFR T790M inhibitor.
AID1298662Selectivity index, ratio IC50 for wild-type EGFR (unknown origin) expressed in baculovirus expression system to IC50 for EGFR T790M/L858R mutant (unknown origin) expressed in baculovirus expression system2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
AID1445468Inhibition of human N-terminal GST-fused EGFR L858R mutant (669 to 1210 residues) expressed in baculovirus using TK-substrate-biotin preincubated for 30 mins followed by substrate addition measured after 15 mins by HTFR assay2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
AID761599Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
AID1350833Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by CellTiter-Glo assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR
AID1625322Antiproliferative activity against human A431 cells expressing wild type EGFR by MTS assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
AID662601Ratio of WZ4002 IC50 to compound IC50 for human NCI-H1975 cells2012Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
AID1365570Inhibition of recombinant human GSt-tagged EGFR T790M/L858R mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system at 1 uM using tyr 04 as substrate after 1 hr by Z'-LYTE assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
AID1458978Inhibition of recombinant human GST-tagged EGFR L858R/T790M double mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 20 mins by HTRF assay2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1345741Human NUAK family kinase 1 (NuaK subfamily)2009Nature, Dec-24, Volume: 462, Issue:7276
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
AID1345572Human erb-b2 receptor tyrosine kinase 4 (Type I RTKs: ErbB (epidermal growth factor) receptor family)2009Nature, Dec-24, Volume: 462, Issue:7276
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
AID1345705Human IL2 inducible T cell kinase (Tec family)2009Nature, Dec-24, Volume: 462, Issue:7276
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
AID1345682Human BLK proto-oncogene, Src family tyrosine kinase (Src family)2009Nature, Dec-24, Volume: 462, Issue:7276
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
AID1345502Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family)2009Nature, Dec-24, Volume: 462, Issue:7276
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
AID1345617Human Bruton tyrosine kinase (Tec family)2009Nature, Dec-24, Volume: 462, Issue:7276
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.64)18.7374
1990's0 (0.00)18.2507
2000's2 (3.28)29.6817
2010's47 (77.05)24.3611
2020's11 (18.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.79 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index129.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (78.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (20.00%)6.00%
Reviews3 (5.45%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other4 (80.00%)84.16%
Other52 (94.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]